FOXC2 Promotes Colorectal Cancer Metastasis by Directly Targeting MET

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2014 Nov 11

PMID 25381815

Citations 51

Authors

Y-M Cui

H-L Jiao

Y-P Ye

C-M Chen

J-X Wang

N Tang

T-T Li

J Lin

L Qi

P Wu

S-Y Wang

M-R He

L Liang

X-W Bian

W-T Liao

Y-Q Ding

Affiliations

Soon will be listed here.

Abstract

Metastasis is the major cause of death in colorectal cancer (CRC). Although multiple genes have been identified to be responsible for the development of CRC, the molecular changes that enable CRC cells to undergo early local invasion and to form distant metastatic colonies still remain largely unknown. Herein, we investigated the role of Forkhead box protein C2 (FOXC2) and explored the underlying mechanisms in invasion and metastasis of CRC. We show that both high FOXC2 expression and nuclear localization of FOXC2 are significantly correlated with advanced TNM (T=primary tumor; N=regional lymph nodes; M=distant metastasis) stages. FOXC2 enhanced the invasive abilities of CRC cells in vitro and promoted local invasion and distant metastasis in an orthotopic mouse metastatic model of CRC. Microarray analysis revealed that overexpression of FOXC2 increased the proto-oncogene MET tyrosine kinase expression and activated the hepatocyte growth factor (HGF)-MET signaling pathway. Furthermore, luciferase reporter assays and chromatin immunoprecipitation assays revealed that FOXC2 directly associated with MET promoter to increase the transcriptional activity of MET. Inhibition of MET attenuates the invasive phenotype and metastatic potential of FOXC2-overexpressing CRC cells, indicating that MET is a major mediator of FOXC2-promoted metastasis. In addition, FOXC2 expression was positively correlated with MET expression in CRC tissue samples. Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling via inducing MET expression, highlighting FOXC2 as a potential therapeutic target for preventing or reducing metastasis in CRC.

Citing Articles

Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover.

Ma Y, Wang R, Liao J, Guo P, Wang Q, Li W Cell Death Discov. 2024; 10(1):454.

PMID: 39468027 PMC: 11519634. DOI: 10.1038/s41420-024-02220-y.

MicroRNAs as the critical regulators of Forkhead box protein family during gynecological and breast tumor progression and metastasis.

Taghehchian N, Lotfi M, Zangouei A, Akhlaghipour I, Moghbeli M Eur J Med Res. 2023; 28(1):330.

PMID: 37689738 PMC: 10492305. DOI: 10.1186/s40001-023-01329-7.

Formin-like 2 promotes angiogenesis and metastasis of colorectal cancer by regulating the EGFL6/CKAP4/ERK axis.

He G, Li W, Zhao W, Men H, Chen Q, Hu J Cancer Sci. 2023; 114(5):2014-2028.

PMID: 36715549 PMC: 10154862. DOI: 10.1111/cas.15739.

HSF4 promotes tumor progression of colorectal cancer by transactivating c-MET.

Zhang W, Zhang X, Cheng P, Yue K, Tang M, Li Y Mol Cell Biochem. 2022; 478(5):1141-1150.

PMID: 36229759 DOI: 10.1007/s11010-022-04582-2.

Reduction of Metastasis via Epigenetic Modulation in a Murine Model of Metastatic Triple Negative Breast Cancer (TNBC).

Zylla J, Hoffman M, Plesselova S, Bhattacharya S, Calar K, Afeworki Y Cancers (Basel). 2022; 14(7).

PMID: 35406526 PMC: 8996906. DOI: 10.3390/cancers14071753.

References

Mazzone M, Comoglio P . The Met pathway: master switch and drug target in cancer progression. FASEB J. 2006; 20(10):1611-21. DOI: 10.1096/fj.06-5947rev. View

Liu C, Park M, Tsao M . Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene. 1992; 7(1):181-5. View

Liao W, Jiang D, Yuan J, Cui Y, Shi X, Chen C . HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res. 2011; 17(11):3569-78. DOI: 10.1158/1078-0432.CCR-10-2533. View

Zhu J, Song Y, Wang Z, Gao P, Wang M, Dong Y . The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology. 2013; 62(7):1038-48. DOI: 10.1111/his.12132. View

Duffy M, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R . Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007; 43(9):1348-60. DOI: 10.1016/j.ejca.2007.03.021. View

Valastyan S, Weinberg R . Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-92. PMC: 3261217. DOI: 10.1016/j.cell.2011.09.024. View

Di Renzo M, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L . Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995; 1(2):147-54. View

de Oliveira A, Matos D, Logullo A, Morini da Silva S, Artigiani Neto R, Longatto Filho A . MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res. 2009; 29(11):4807-11. View

Park S, Gadi J, Cho K, Kim K, Kim S, Jung H . The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin β1 expression. Bone. 2011; 49(3):428-38. DOI: 10.1016/j.bone.2011.05.012. View

10.

Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M . c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res. 2003; 9(4):1480-8. View

11.

Shibue T, Brooks M, Inan M, Reinhardt F, Weinberg R . The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov. 2012; 2(8):706-21. PMC: 3418422. DOI: 10.1158/2159-8290.CD-11-0239. View

12.

Jiang W, Pang X, Wang Q, Shen Y, Chen X, Xi J . Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer. 2011; 13(4):280-7. DOI: 10.1016/j.cllc.2011.11.005. View

13.

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

14.

Birchmeier C, Birchmeier W, Gherardi E, Vande Woude G . Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4(12):915-25. DOI: 10.1038/nrm1261. View

15.

Mortazavi F, An J, Dubinett S, Rettig M . p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res. 2010; 8(5):762-74. DOI: 10.1158/1541-7786.MCR-10-0004. View

16.

Stein U, Schlag P . Clinical, biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res. 2007; 176:61-80. DOI: 10.1007/978-3-540-46091-6_7. View

17.

Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I . MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med. 2008; 15(1):59-67. DOI: 10.1038/nm.1889. View

18.

Xue Y, Cao R, Nilsson D, Chen S, Westergren R, Hedlund E . FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci U S A. 2008; 105(29):10167-72. PMC: 2481379. DOI: 10.1073/pnas.0802486105. View

19.

Mani S, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N . Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A. 2007; 104(24):10069-74. PMC: 1891217. DOI: 10.1073/pnas.0703900104. View

20.

Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S . c-Met is essential for wound healing in the skin. J Cell Biol. 2007; 177(1):151-62. PMC: 2064119. DOI: 10.1083/jcb.200701086. View